Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499964 | 1.00 | MEN1 (0.46) | MEN1ALDH1A1CYP1A2CYP2C9HPGD | |
| Hydrochloric Acid SCHEMBL4889627 | 0.99 | MEN1 (0.45) | MEN1ALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL8779971 | 0.91 | MEN1 (0.46) | MEN1ALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL8779858 | 0.86 | — | — | |
| SCHEMBL8779876 | 0.86 | — | — | |
| SCHEMBL29496156 | 0.84 | KMO (0.44) | MEN1ALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL8779888 | 0.83 | APEX1 (0.44) | — | |
| SCHEMBL8779864 | 0.83 | APEX1 (0.44) | — | |
| SCHEMBL8779882 | 0.81 | GGPS1 (0.43) | — | |
| Propionic Acid SCHEMBL25431974 | 0.74 | BACE1 (0.51) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | claimed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | claimed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | claimed |
| US-9579299-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2017-02-28 | — | — | US | disclosed |
| WO-2016027259-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2016-02-25 | — | — | WO | disclosed |
| US-20140256709-A1 | CNS PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | TARGIA PHARMACEUTICALS (IL) | 2014-09-11 | — | — | US | disclosed |
| US-20140194514-A1 | TOPICAL FORMULATIONS | TARAXOS INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8729070-B2 | CNS pharmaceutical compositions and methods of use | TARGIA PHARMACEUTICALS (IL) | 2014-05-20 | — | — | US | disclosed |
| US-20130209585-A1 | Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy | KIM STANLEY (US) | 2013-08-15 | — | — | US | disclosed |
| US-20030082214-A1 | Topical compositions and methods for treating pain | DISCOVER GROWTH FUND, LLC (VI) | 2003-05-01 | — | — | US | disclosed |
| WO-2003034900-A2 | STERILE, BREATHABLE PATCH FOR TREATING WOUND PAIN | EPICEPT CORPORATION (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003015699-A2 | TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN | EPICEPT CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0879238-B1 | BENZIMIDAZOLE PHOSPHONO-AMINO ACIDS | AMERICAN HOME PROD (US) | 2001-11-14 | — | — | EP | disclosed |
| US-5864040-A | Benzimidazole phosphono-amino acids | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0879238-A1 | BENZIMIDAZOLE PHOSPHONO-AMINO ACIDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997025335-A1 | BENZIMIDAZOLE PHOSPHONO-AMINO ACIDS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | MEN1 1091/4885ALDH1A1 3257/4885CYP1A2 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.